Background: Diabetic nephropathy (DN) is a major cause of end-stage renal disease and proteinuria is one of the most prominent clinical manifestations. The expression of Vitamin D receptor (VDR) in patients with chronic kidney diseases was decreased, while VDR agonists could partially alleviate the proteinuria of DN in animal models. The present study was designed to determine the expression of VDR in renal tissues and its relationship with proteinuria the diabetic model db/db mice. Methods: The regulation effects of VDR on the Wnt signaling pathway were analyzed using RNA interference and VDR agonist paricalcitol. Results: With the increase in age of the db/db mice, the VDR protein and mRNA levels in renal tissues were decreased, proteinuria increased, and the protein and mRNA levels of GSK-3β of and β-catenin increased. Paricalcitol treatment resulted in the up-regulation of VDR and down-regulation of GSK-3β and β-catenin, indicating that VDR had a regulatory effect on the Wnt signaling pathway. Conclusion: VDR activation could reduce proteinuria of DN mice and alleviate highglucose-induced injury of kidneys and podocytes by regulating the key molecules of Wnt signaling pathway.
Introduction
Diabetes poses a major public health problem worldwide, with ever-increasing incidence and prevalence in recent years. Diabetic nephropathy (DN) is one of the most Guo et al.: Proteinuria and High-Glucose-Induced Injury of Kidneys and Podocytes Tables   Table 1. The sequences Table 2 . Conditions of qRT-PCR Table 1 . The sequences of primers used in the present study
Real-time PCR
Total RNA was extracted using Trizol reagent (Invitrogen Inc.), according to the manufacturer's instructions. The RNA purity was determined using absorbance at 260 and 280 nm(A260/280) and the cDNA was synthesized using 2μg of RNA and the First StcDNA Synthesis Kit (Fermentas, Burlington, Canada) using the M-MuLV Reverse Transcriptase and random primers. The sequences of specific primers used in the present study are shown in Table 1 . The cDNA (1 μL) was mixed with the forward and reverse primers (0.5μL each), 2×PCR MasterMix (12.5μL; Life Technologies Co., Grand Island, NY, USA) and deionized water (in total volume of 25μL); the reaction was performed in a thermocycler (BD Diagnostics, Sparks, MD, USA) under the conditions of cycle shown in Table 2 . After completion of the reaction to confirm the amplification curve and melting curve, the CT values of the corresponding index was calculated as ΔΔCT by the following formula: ΔΔCT：(CtA2-CtB2)-(CtA1-CtB1). Wherein A represents the target gene Ct values, B for reference gene Ct values, 1 and 2 represent different treatment groups. The experiment was repeated three times, and the average values were reported. The results calculated by the target gene treatment group with 2-ΔΔCT times higher than the target gene were expressed. The PCR products were separated by 2.0% agarose gel electrophoresis. The Image J image software (National Institutes of Health, Bethesda, MD, USA) was used to quantify the grayscale values.
Western blotting analysis
The total cellular proteins were obtained from each group using the RIPA lysis buffer (Dingguo Changsheng Biotech Co., Ltd., Beijing, China). Proteins were quantified using a BCA protein assay kit (Dingguo Changsheng Biotech Co., Ltd.). The samples with equal amount of total proteins (20µg) were separated using 10% SDS-PAGE and were transferred on PVDF membranes (Roche, Mannheim, Germany). The membranes were blocked using 5% powdered milk diluted in TBS containing 0.05% Tween 20 (TBST) for 1h. 
Animals and treatments
All the animal experimental procedures were reviewed and approved by the Ethics Committee of the First Affiliated Hospital of Zhengzhou University. The C57BL/KsJ db/db, six-week, male mice and agematched db/m mice were purchased from Nanjing Center for Experimental Animals (Nanjing, China). The mice were housed at 25°C and 50-60% relative humidity, in a 12h/12h light/dark cycle, with free access to food and water. The mice were randomly assigned to four groups (20 mice per group): 1) db/m normal control group (group C, untreated), 2) db/db normal control group (group N, untreated), 3) db/db vehicletreated group (group D, 0.3μg/kg, by intraperitoneal injection, i. P.), and 4) db/db paricalcitol-treated group (group P, equal amounts of dimethylsulfoxide, i.p.). The treatments began at the age of 10 weeks and ended at 22 weeks old; all the treatments were performed three times a week (Days 1, 3, and 5 each week). Some of these mice were sacrificed at Weeks 10, 14, 18, and 22, respectively. All the mice were killed under 10% chloral hydrate anesthesia and the kidneys were then isolated.
Measurements of renal function, blood glucose, and serum lipids
For 24-h complete urine collection, the mice were placed individually in metabolic cages with free access to food and water. Urine albumin and creatinine were measured by the Kidney Lab of First Affiliated Hospital of Zhengzhou University. The blood samples were collected from the tail veins after fasting for 8 h (during experiments), and by cardiac puncture (at the end of experiments). Serum levels of glucose (GLU), creatinine, urea nitrogen, uric acid, triglyceride (TG), cholesterol (TC), glycated serum protein (GSP) and albumin/creatinine ratios were all assayed using an Automatic Biochemistry Analyzer CS-400 (Changchun Dirui Medical Technology Co Ltd, Changchun, China).
Histology and immunofluorescence
The removed kidneys were weighed and the cortices were then separated. The left cortices were snapfrozen for Western blotting and real-time PCR analyses, and the right cortices were used for pathological analyses. The renal tissues were fixed in Bouin's solution, embedded in paraffin, cut into 5-mm sections, and stained with periodic acid-Schiff (PAS) and H&E staining. For immunofluorescence analysis, the renal cortex of 1 mm × 1 mm × 1 mm was fixed in 2.5% glutaraldehyde and the remaining kidney tissues were fixed in 4% paraformaldehyde.
The podocytes were stimulated by 25 mmol/Lof glucose for 36h, and fixed in 4°C 4% paraformaldehyde for 20 min and 0.6% Tween-20 for 15min, and then blocked with 5% BSA blocking solution for 20 min at room temperature. The cells were exposed to antibodies against VDR, Nephrin, Podocin, α-SMA, and MMP9 overnight. The cells were washed three times with PBS, and then incubated with the Alexa Fluor 488 goat anti-rabbit IgG (H+L) (green) and the Alexa Fluor 594 donkey anti-mouse IgG (H+L) (red) (Invitrogen Inc., Carlsbad, CA, USA) at 37°C for 1 h. The fluorescence was observed under a fluorescence microscope (Olympus, CX31-32RFL, Japan). 
Results

Effects of VDR expression level on gene expression and barrier function of podocytes
In order to determine the relationship between the VDR expression and phenotype and barrier function of podocytes, we used a siRNA to knock down the expression of VDR. As shown in Fig. 1 , Western blotting analyses demonstrated that, compared with control groups, VDR siRNA resulted in the down-regulation of the protein levels of VDR, nephrin, and podocin (P<0.05) and the up-regulation of the protein levels of α-SMA and MMP9 (P<0.05).The results of qRT-PCR analyses indicated that ( Fig. 2) , the mRNA expression levels of VDR, nephrin, and podocin were all down-regulated, compared with the control groups (P<0.05) and the mRNA expression levels of α-SMA and MMP9 were up-regulated (P<0.05). The results of the albumin flow indicated that VDR siRNA treatment resulted in an increase in the albumin flow of the podocytes(P<0.05).
Effects of paricalcitol on gene expression of the Wnt signaling pathway
Our previous experimental results have found that, under high glucose conditions, the expression of GSK-3β and β-catenin is increased, indicating that the activity of Wnt signaling pathway is increased. In the present study, Western blotting analyses indicated that, compared with the NG group, the expressions of α-SMA, MMP9,GSK-3β, and β-catenin were up-regulated and the levels of VDR, nephrin, and podocin were decreased in the high glucose group, which was reversed by paricalcitol (Fig. 3) .The qRT-PCR results indicated that, compared with the NG group, the mRNA expressions of α-SMA, MMP9,GSK-3β and β-catenin were up-regulated and the expression levels of VDR, nephrin, and podocin were decreased in the high glucose group, which was reversed by paricalcitol treatment (Fig. 4) .
Effects of GSK-3β siRNA on gene expressions of the Wnt signaling pathway
We next determined the influence of VDR on β-catenin under the condition of siRNA knockdown ofGSK-3β. The results of Western blotting analyses indicated that, compared with control groups,GSK-3β siRNA resulted in the up-regulation of VDR, nephrin, and podocin (P<0.05)and the down-regulation of α-SMA,MMP9,GSK-3β, and β-catenin (P<0.05, Fig. 5 ), which was not affected by paricalcitol treatment. The qRT-PCR analyses indicated that, compared with control groups, GSK-3β siRNA treatment resulted in the increased mRNA expression of VDR, nephrin, and podocin and the decreased mRNA levels of α-SMA,MMP9,GSK-3β, and β-catenin (P<0.05), which was not affected by paricalcitol treatment (Fig. 6) . Fig. 2 . qRT-PCR analysis for gene expression after VDR siRNA knock out.*: compared with NG group and scrsiRNA group, p<0.05 for VDR;#: compared with NG group and scrsiRNA group, p<0.05 for GSK-3β;&: compared with NG group and scrsiRNA group, p<0.05 for β-catenin;α: compared with NG group and scrsiR-NA group, p<0.05 for podcin;β: compared with NG group and scrsiRNA group, p<0.05 for nephrin;γ: compared with NG group and scrsiRNA group, p<0.05 for α-SMA;δ: compared with NG group and scrsiRNA group, p<0.05 for MMP9. Fig. 3 . Western blotting analysis for the effects of paricalcitol on protein expression.*: compared with NG group, p<0.05 for VDR;#: compared with NG group, p<0.05 for GSK-3β;&: compared with NG group, p<0.05 for β-catenin;α: compared with NG group, p<0.05 for podcin;β: compared with NG group, p<0.05 for nephrin;γ: compared with NG group, p<0.05 for α-SMA;δ: compared with NG group, p<0.05 for MMP9.*p: compared with 25G group, p<0.05 for VDR;#p: compared with 25G group, p<0.05 for GSK-3β;&p: compared with 25G group, p<0.05 for β-catenin;αp: compared with 25G group, p<0.05 for podcin;βp: compared with 25G group, p<0.05 for nephrin;γp: compared with 25G group, p<0.05 for α-SMA;δp: compared with 25G group, p<0.05 for MMP9. 
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Effects of paricalcitol on proteinuria and kidney injury in DN mice
We next investigated whether paricalcitol was effective in ameliorating proteinuria in mice. The body weight, absolute body fat, food intake, water intake, and urine volume of db/ db mice were consistently increased with age, compared with the normal control mice ( Table  4 ). The 6-week old db/db diabetic mice also exhibited significantly higher blood glucose levels, which was consistently increased throughout the study period, compared with the normal control animals ( Table 5 ). Early renoprotection effects of parcalcitol were examined by measuring the 24-h urinary albumin excretion (UAE) in the db/db mice, compared with the controls. We treated the db/db mice with paricalcitol starting at 10 weeks old and demonstrated that paricalcitol significantly ameliorated urinary albumin excretion in db/db mice after only four weeks of treatment (Table 6 ). The 24-h urine protein levels of Scr and BUN were increased significantly in group D and group N compared with group C, while decreased in group P compared with groups D and N (Table 6 ). This reduction of urinary albumin was maintained throughout the duration of the study. Collectively, the above observations revealed that an early stage of DN occurred at 6-week old. In comparison with groups D and N, the treatment did not affect serum levels of triglycerides, cholesterol, glucose, and glycated We further examined the effects of paricalcitol on the expression of VDR inrenal tissues of the db/db mice and found that with the increase of week-age of db/db mice, the expression of VDR was gradually decreased, which was reversed by paricalcitol (Figures 7 and  8) . With the increase of week-age of db/db mice, the expression of GSK-3β and its downstream molecule β-catenin, the key molecules in Wnt signaling pathway, were gradually increased, which was reversed by paricalcitol (Fig. 9) . In kidney tissues of the db/db mice, with the increase of week-age, the expressions of nephrin and podocin, the marker proteins of podocyte, were gradually decreased, and the expressions of a-SMA and MMP9, the marker proteins of mesenchymal, were gradually increased, which were reversed by paricalcitol (Figures 10 and 11) . Under the electron microscope, glomerular basement membrane in the renal tissues of db/db mice and db/ db-D mice showed irregular thickening, had not deposited electron dense but with visible Compared with db / m P <0.05; #: and 10w db/db compared P <0.05; Δ: with 14w db/db compared P <0.05; π: and 18w db/db compared to P <0.05.E, F * in: the db / m compared to P <0.05; #: P compared with db/db group and db/db-D group <0.05). foot process fusion; paricalcitol treatment improved the morphology: glomerular basement membrane was homogeneous smooth without thickening and foot process fusion was no visible. Paricalcitol alleviated the foot process fusion of the podocytes in the db/db mice (Fig. 12) . We also examined whether this protection was associated with renal function in the db/ db mice. A decline in glomerular filtration rate (GFR) was observed in mice of 17-weeks or older; as a result, an elevation in serum creatinine (SCR) was frequently reported at 16 weeks or older (Table 7) . Paricalcitol significantly reduced the SCR levels in the db/db mice, indicating an improvement in the renal function.
Discussion
Vitamin D and VDR could provide possible renoprotection against DN [12] . More fibronectin and less nephrin are expressed in the VDR knockout mice compared to diabetic wild-type mice. In the present study, down-regulation of VDR by siRNA decreased the expression of nephrin and podocin and increased the expression of α-SMA and MMP9.
The Wnt signaling pathway plays an important role in the regulation of differentiation of cellar morphology and function and β-catenin is a multifunctional protein and is a key factor involved in classic Wnt signaling. Under normal physiological conditions, the Wnt signaling pathway in kidney is "static", axin, APC, and GSK-3β combine with β-catenin, making β-catenin phosphorylated [19] [20] [21] .In our previous experiment, the expressions of GSK-3β 
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Cellular Physiology and Biochemistry and β-catenin were increased under the high glucose condition, and consequently the expression of mesenchymal marker proteins were increased, and barrier function of podocytes was destroyed. And the expression of VDR and β-catenin were co-localized in the nuclei. The expression of VDR was decreased after using GSK-3β inhibitor to interfere the expression of GSK-3β in the renal tissues of db/db Glomerular basement membrane showed irregular thicken, had not deposited electron dense and the foot process fusion was visible; compared with db/ db mice, the lesions of renal tissue in db/ db-P mouse was improved. Glomerular basement membrane in renal tissue of db/m mice was homogeneous smooth without thickening, and foot process fusion was no visible. mice, but the interaction of VDR with GSK-3β and β-catenin remains unclear. The present study showed that with down-regulation of GSK-3β expression, the expression of β-catenin was decreased and the expression of VDR increased. In the present study, the db/db mice at six weeks of age exhibited hyperglycemia and albuminuria. With increasing age, the disease progressed and kidney function deteriorated further, resulting in a significant rise in albuminuria and renal fibrosis. Though there were some studies about the roles of some potential chemicals or drugs on diabetic kidney injury, our study showed the new role and mechanism of VDR agonist [22, 23] . The results from the present study demonstrated that paricalcitol possessed an impressive renal protective efficacy in DN. Considering the pathologic sequences of this model, it is conceivable that the reno-protective effect of paricalcitol may be primarily attributable to its prevention of podocyte injury. This notion was further substantiated by the observations that paricalcitol prevented the loss of podocyte-specific nephrin, podocin. Interestingly, this anti-proteinuric action of this vitamin D analogs has also been reported in several clinical studies in patients with chronic renal insufficiency, as well as in other animal models of proteinuric kidney diseases [24] . Therefore, it is becoming clear that paricalcitol is quite effective in alleviating podocyte injury and proteinuria under different circumstances [25, 26] .
Hyperglycemia leads to nephropathy by various mechanisms, such as increased endothelial cell permeability to albumin, hypertrophy, thickening of the basement membrane and renal fibrosis [27, 28] . In the present study, our data demonstrated that the expressions of GSK-3β, β-catenin, α-SMA, and MMP9 were increased under high glucose condition, and these changes were attenuated by paricalcitol pretreatment. Additionally, paricalcitol could reverse the decrease in the levels of VDR, nephrin, and podocin caused by high glucose, further confirming its effects on prevention of renal injury in DN. These results may provide a basis for further rationale use of this drug in the clinic to treat and prevent DN.
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